Invited Participants

ISPOR 9th Patient Representatives Roundtable
(Supported by Novartis, Pfizer, Roche, and Takeda)
Monday, 6 November 2017 | 12:30 – 17:00 | SEC - Gallery Bistro
ISPOR 20th Annual European Congress – Glasgow, Scotland, UK

Patient Representatives

Nicola Bedlington
Secretary General
European Patients’ Forum (EPF)
Brussels, Belgium

Christophe Bintener
Project Officer
Alzheimer Europe
L-1417 Luxembourg

Rob Camp
Patient Advocate
EUPATI Spain and EURORDIS
Barcelona, Spain

Dominique Hamerlijnck
Patient Representative
Lung Foundation Netherlands (Longfonds)
Amersfoort, the Netherlands

Paola Kruger
Patient Expert (EUPATI)
Accademia dei Pazienti Onlus Advocacy
Rome, Italy

Michael Längsfeld
Working Group Head Choroideremia / Head of Department Regional Groups, Pro Retina Germany
Member of Board of Directors, Choroideremia Research Foundation United States of America
Bad Nauheim, Germany

Zorana Maravic
Director, Group and Project Development
EuropaColon
Belgrade, Serbia

Matthew May, BS
EUPATI Coordinator
European Patients Forum (EPF)
Brussels, Belgium
Invited Participants

**Robert McBurney, PhD, BSc**  
Chief Executive Officer, *Accelerated Cure Project for Multiple Sclerosis*  
Founder and Director, *Optimal Medicine Ltd.*  
Waltham, MA, USA

**Derick Mitchell, PhD, BSc. (Hons)**  
Chief Executive  
*Irish Platform for Patient Organisations, Science & Industry (IPPOSI)*  
Dublin, Ireland

**Kate Morgan**  
Policy and Public Affairs Manager  
*Myeloma Patients Europe (MPE)*  
Brussels, Belgium

**Jamie O’Hara**  
Chair, EHC Data and Economics Committee  
*European Haemophilia Consortium (EHC)*  
Brussels, Belgium

**Bettina Ryll, MD, PhD**  
Founder, *Melanoma Patient Network Europe (MPNE)*  
Chair, Patient Advocates Working Group, *European Society for Medical Oncology (ESMO)*  
Uppsala, Sweden

**Jayne Spink**  
Chief Executive Officer  
*Genetic Alliance UK*  
London, United Kingdom

**Russell Wheeler**  
Patient Advocate  
*Leber’s Hereditary Optic Neuropathy*  
Merusac, France

**Payer and HTA Stakeholder Participants**

**Michael Barry, MD, PhD, FRCPI**  
Clinical Director, National Centre for Pharmacoeconomics  
*St. James's Hospital*  
Dublin, Ireland

**Ken Bond, MA**  
Director, Patient Engagement, Ethics, and International Affairs  
*Canadian Agency for Drugs and Technologies in Health (CADTH)*  
Ottawa, ON, Canada
Invited Participants

Jennifer Dickson
Public Involvement Coordinator
Scottish Medicines Consortium
Glasgow, Scotland

Chantal Guilhaume, PharmD
Scientific Project Manager, EUnetHTA JA3
Direction de l'Evaluation Médicale, Economique et de Santé Publique (DEMESP)
Haute Autorité de Santé (HAS)
Saint-Denis La Plaine, France

Heidi Livingstone
Public Involvement Adviser
National Institute for Health and Care Excellence (NICE)
London, United Kingdom

Sheela Upadhyaha
Associate Director, Highly Specialised Technologies
National Institute for Health and Care Excellence (NICE)
London, United Kingdom

John Watkins, PharmD, MPH, BCPS
Pharmacy Manager, Formulary Development
Premera Blue Cross
Mountlake Terrace, WA, USA

Karen Worley, PhD
Research Leader, Comprehensive Health Insights
Humana, Inc.
Cincinnati, OH, USA

Research Stakeholder Participants

Karen Facey, PhD
Honorary Research Fellow and Evidence Based Healthcare Policy Consultant
University of Edinburgh
Edinburgh, United Kingdom

Rachel Harrington
Patient Centered SIG Chair, ISPOR
PhD Candidate, Dept. of Pharmacy Systems, Outcomes, & Policy, College of Pharmacy
University of Illinois at Chicago
Chicago, IL, USA

Sandra Nestler-Parr, PhD, MSc
Managing Director, Rare Access Ltd.
Trustee, Alpha-1 UK Support Group
London, United Kingdom
Invited Participants

Shelby D. Reed, PhD, RPh
President, ISPOR
Professor, Duke University
Durham, NC, USA

Gurmit Sandhu, B Pharm (Hons), MBA, MPH
Patient Engagement Specialist
Gurmit Sandhu Consulting GmbH
Basel, Switzerland

Regulatory and Government Participants

Nathalie Bere
Patient Liaison Coordinator
EMA - European Medicines Agency
London, United Kingdom

Flora Giorgio
Policy Officer, DG Health and Consumers
European Commission
Brussels, Belgium

Industry Stakeholder Participants

Scott Campbell, BS
Associate Director, Patient Advocacy
Takeda Pharmaceuticals International Co.
Cambridge, MA, USA

Nigel Cook, PhD
Head of Decision Support, Global Patient Access
Novartis Pharma
Basel, Switzerland

Irmi Gallmeier
Senior International Health Policy Leader, Global Health Policy
F. Hoffmann-La Roche Ltd
Basel, Switzerland

Louise Huneault, BSN, MEd
Head, Patient Relations Hematology, Region Europe
Novartis Pharma AG
Basel, Switzerland
Invited Participants

Judith Luker, BA
International Alliance Development Department, Global Policy and International Public Affairs
Pfizer
London, United Kingdom

Mirko Ristanovic, MD
Director, Pricing Dynamics – Global Pricing: Patient & Health Impact
Pfizer
Belgrade, Serbia

Dorothy Romanus, RPh, MSc, PhD
Director, Global Outcomes Research
Takeda Pharmaceuticals International Co.
Cambridge, MA, USA

Claudine Sapede
Global HTA & Payment Policy Lead, Global Pricing and Market Access
F. Hoffmann-La Roche Ltd
Basel, Switzerland

ISPOR Staff – Lawrenceville, NJ, USA

Nadia Naaman, Senior Director, Scientific & Health Policy Initiatives
Theresa Tesoro, MSN, Associate Director, Scientific & Health Policy Initiatives
Clarissa Cooblall, MPH, Manager, Scientific & Health Policy Initiatives